Beclometasone & formoterol & glycopyrronium (Trimbow)

BNF:
Respiratory
Status:
Grey
Decision Date:
None
 

Comments

COPD (Trimbow 88/5/9 NEXThaler DPI): GREY 1st line triple combination

COPD (Trimbow 87/5/9 MDI): GREY (Decision date - October 2017)

 Indicated for the maintenance treatment of moderate to severe COPD

  • Triple therapy is reserved for exceptional use in severe disease in the presence of persistent exacerbation's despite other treatments.
  • Triple therapy in a single inhaler may be preferable for people who have difficulty using more than one device or who find their medication regimen difficult or confusing, and have trouble complying with treatment. However triple therapy lack flexibility and makes it difficult to amend the individual medicines if treatment needs changing for any reason.
  • Use of this combination product is cheaper than using the separate components.

Asthma (Trimbow 87/5/9 MDI and Trimbow 172/5/9 MDI): GREY after specialist initiation: to be used in severe asthma with a demonstrated airflow obstruction. (Decision date - August 2021)

Grey Drug Classifications

  • 8. Exceptionality where a small cohort of patients may benefit from prescribing can be identified

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app